Claimempirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →importance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

CETP inhibitors substantially lowered LDL cholesterol but failed to reduce cardiovascular events

Not yet assessed. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.

Decomposition

How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.

argumentEarly CETP outcome trials disappointed despite LDL loweringforThis argument, if it holds, bears in favour of the claim.constitution →

Because torcetrapib lowered LDL cholesterol yet increased cardiovascular events and mortality and evacetrapib lowered LDL cholesterol without reducing cardiovascular events, and given that a third agent, dalcetrapib, was likewise stopped for futility, the class's LDL lowering appeared not to translate into cardiovascular benefit.

argumentLater CETP evidence contradicts the blanket generalizationagainstThis argument, if it holds, weighs against the claim.constitution →

Because anacetrapib significantly reduced major coronary events in the REVEAL trial, the class did not uniformly fail to reduce cardiovascular events; the ongoing development of obicetrapib, which lowers LDL cholesterol by roughly 30 percent with an outcomes trial underway, further undercuts the blanket generalization.

See how these fit together on the map

or create a grant for this whole area →

Provenance

Where this claim has been said, linked to its canonical form.

The one CETP inhibitor that was demonstrated to reduce cardiovascular risk, anacetrapib, did not progress

https://www.jacc.org/doi/10.1016/j.jacc.2025.07.056extraction 0.80

A pooled analysis of obicetrapib trials in JACC; its introduction recounts the class history and asserts in its own voice that anacetrapib was demonstrated to reduce cardiovascular risk, denying the blanket generalization that CETP inhibitors failed to reduce events.

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

https://www.tctmd.com/news/anacetrapib-finds-modest-success-where-all-other-cetp-inhibitors-failedextraction 0.70

News coverage of the REVEAL trial presented at ESC 2017; the piece asserts that anacetrapib succeeded in reducing coronary events where the other CETP inhibitors had failed, denying the class-wide failure claim while affirming its historical core.

Cite this claim: a formal citation with its evidence attached

Contribute

Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.

Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.